Please try another search
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101 which is in Phase II trials for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis type 1. The company is also developing JNS108 which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer’s disease; and JNS107, which is in Phase II trials for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; and JNS110 for traumatic brain injury/concussion. Jupiter Neurosciences, Inc. was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was incorporated in 2015 and is based in Jupiter, Florida.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review